Elevance Health, Inc. (NYSE:ELV - Free Report) - Investment analysts at Wolfe Research cut their Q3 2025 earnings per share (EPS) estimates for Elevance Health in a research note issued on Monday, October 6th. Wolfe Research analyst J. Lake now expects that the company will post earnings of $5.22 per share for the quarter, down from their previous forecast of $8.69. The consensus estimate for Elevance Health's current full-year earnings is $33.96 per share. Wolfe Research also issued estimates for Elevance Health's Q4 2025 earnings at $3.95 EPS, FY2025 earnings at $30.00 EPS, Q1 2026 earnings at $10.10 EPS, Q2 2026 earnings at $8.31 EPS, Q3 2026 earnings at $6.27 EPS, Q4 2026 earnings at $2.74 EPS, FY2026 earnings at $27.50 EPS, Q1 2027 earnings at $12.07 EPS, Q2 2027 earnings at $9.62 EPS, Q3 2027 earnings at $7.56 EPS, FY2027 earnings at $33.50 EPS, FY2028 earnings at $42.00 EPS and FY2029 earnings at $48.75 EPS.
Other equities research analysts have also recently issued research reports about the company. Guggenheim boosted their price objective on Elevance Health from $360.00 to $398.00 and gave the company a "buy" rating in a research note on Wednesday. Barclays set a $395.00 price objective on Elevance Health and gave the company an "overweight" rating in a research note on Thursday. UBS Group reduced their price objective on Elevance Health from $435.00 to $425.00 and set a "buy" rating for the company in a research note on Friday, September 5th. Robert W. Baird dropped their target price on Elevance Health from $492.00 to $297.00 and set a "neutral" rating on the stock in a report on Friday, July 25th. Finally, Argus reissued a "hold" rating on shares of Elevance Health in a report on Monday, July 21st. Twelve investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $419.94.
Get Our Latest Stock Report on ELV
Elevance Health Price Performance
Shares of NYSE ELV opened at $362.47 on Thursday. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. Elevance Health has a twelve month low of $273.71 and a twelve month high of $510.24. The stock has a 50 day moving average of $312.01 and a two-hundred day moving average of $360.14. The stock has a market cap of $81.62 billion, a P/E ratio of 15.42, a P/E/G ratio of 1.31 and a beta of 0.59.
Elevance Health (NYSE:ELV - Get Free Report) last issued its quarterly earnings data on Thursday, July 17th. The company reported $8.84 earnings per share for the quarter, missing analysts' consensus estimates of $9.30 by ($0.46). Elevance Health had a net margin of 2.83% and a return on equity of 17.59%. The firm had revenue of $49.42 billion during the quarter, compared to analysts' expectations of $48.26 billion. During the same quarter in the prior year, the firm posted $10.12 EPS. Elevance Health's quarterly revenue was up 14.3% compared to the same quarter last year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently bought and sold shares of ELV. Norges Bank acquired a new position in Elevance Health during the second quarter worth $1,148,379,000. Nuveen LLC acquired a new stake in Elevance Health in the first quarter valued at $789,943,000. Sanders Capital LLC grew its holdings in Elevance Health by 24.7% in the second quarter. Sanders Capital LLC now owns 5,825,208 shares of the company's stock valued at $2,265,773,000 after purchasing an additional 1,152,440 shares during the last quarter. Beutel Goodman & Co Ltd. acquired a new stake in Elevance Health in the second quarter valued at $293,141,000. Finally, Vanguard Group Inc. grew its holdings in Elevance Health by 3.2% in the second quarter. Vanguard Group Inc. now owns 22,856,898 shares of the company's stock valued at $8,890,419,000 after purchasing an additional 704,790 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company's stock.
Insiders Place Their Bets
In other Elevance Health news, Director Susan D. Devore acquired 1,200 shares of the company's stock in a transaction that occurred on Tuesday, August 19th. The shares were purchased at an average price of $312.15 per share, with a total value of $374,580.00. Following the completion of the acquisition, the director directly owned 3,502 shares of the company's stock, valued at approximately $1,093,149.30. The trade was a 52.13% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Gail Boudreaux acquired 8,500 shares of the company's stock in a transaction that occurred on Friday, July 18th. The shares were acquired at an average cost of $286.94 per share, for a total transaction of $2,438,990.00. Following the acquisition, the chief executive officer directly owned 151,020 shares of the company's stock, valued at $43,333,678.80. This trade represents a 5.96% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 0.29% of the company's stock.
Elevance Health Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Thursday, September 25th. Stockholders of record on Wednesday, September 10th were issued a $1.71 dividend. The ex-dividend date of this dividend was Wednesday, September 10th. This represents a $6.84 dividend on an annualized basis and a dividend yield of 1.9%. Elevance Health's payout ratio is presently 29.11%.
Elevance Health Company Profile
(
Get Free Report)
Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Elevance Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elevance Health wasn't on the list.
While Elevance Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
